Compare STMicroelectronics NV (STM) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
STMicroelectronics NV vs Spyre Therapeutics Inc. Common Stock — how do they compare? STMicroelectronics NV trades at $45.12 (market cap $43.80B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: STMicroelectronics NV is far larger — about 5.8× Spyre Therapeutics Inc. Common Stock's market cap, and STMicroelectronics NV pays a 0.73% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold STMicroelectronics NV for 65 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| STM | SYRE | |
|---|---|---|
Market Cap | $43.80B | $7.52B |
Volume | 7,353,071 | 1,441,031 |
Sector | Technology | Health |
52-Week High | $79.91 | $108.92 |
52-Week Low | $21.20 | $22.18 |
Typical Hold Time | 65 Days | 0 Days |
Enterprise Value | $41.32B | $6.52B |
Dividend Yield | 0.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
STM is trading at $46.9, down 7.09% in the last session, with a bearish technical signal. The company shows mixed fundamentals with a high P/E ratio of 94.59 but negative net income margin of -0.39%. Recent Q2 2026 earnings beat expectations with EPS of $0.31 versus $0.26 expected, while Q1 and Q4 2025 missed. Strong cash flow of $555M in 2025 and improving 2026 projections provide some optimism amid current weakness.
The outlook remains cautious with analyst consensus price target of $77.31 suggesting 65% upside potential. Key opportunities include AI data-center revenue projected to exceed $2B in 2027 and automotive sensor innovations. Risks include declining revenue trends from $17.3B in 2023 to $11.8B in 2025 and negative profitability metrics requiring careful monitoring.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About STMicroelectronics NV
A merger between Italian firm SGS Microelettronica and the nonmilitary business of Thomson Semiconductors in France formed STMicroelectronics in 1987. STMicro is a leader in a variety of semiconductor products, including analog chips, discrete power semiconductors, microcontrollers, and sensors. STMicro is an especially prominent chip supplier into the industrial and automotive industries.
Read more on STM →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
